

Table S4. Normal fatty acid oxidation in patient myoblasts compared to control, in basal and pro-inflammatory conditions (TNF- α + IL-1 β).

	Patient		Control	
	Basal conditions	Pro-inflammatory conditions	Basal conditions	Pro-inflammatory conditions
200 nmol of substrate				
C4d5 Butyryl- / IsobutyrylCn	564	631	579	570
C6d5 HexanoylCn	59	35	90	87
C8d5 OctanoylCn / ValproylCn	23	30	128	117
C10d5 DecanoylCn	85	63	295	239
C12d5 LauroylCn	133	109	214	185
C14d5 MyristoylCn	194	168	210	197
C16d5 PalmitoylCn	678	889	723	780
50 nmol of substrate				
C4d5 Butyryl- / IsobutyrylCn	481	479	326	401
C6d5 HexanoylCn	32	36	55	65
C8d5 OctanoylCn / ValproylCn	25	23	92	88
C10d5 DecanoylCn	41	47	159	180
C12d5 LauroylCn	53	38	49	68
C14d5 MyristoylCn	49	27	21	29
C16d5 PalmitoylCn	205	114	104	119